Prefilled Syringes in Biologic Drug Delivery: Innovations in Design and Safety

lauraclark849
Mar 24
20 min read

Updated: Mar 26

Technical Review Article | Open Access | Published 26th March 2026

Prefilled Syringes in Biologic Drug Delivery: Innovations in Design and Safety

Shraddha Mahajan, Ravi Sharma* | EJPPS | 311 (2026) https://doi.org/10.37521/ejpps31104

Back to Journals | Article |Abstract | References | Authors

Abstract

The rapid growth of biologic therapeutics has driven the need for advanced, patient-centric drug delivery systems that ensure safety, stability, and ease of administration. Prefilled syringes (PFS) have emerged as a preferred delivery format for biologics due to their ability to reduce dosing errors, enhance patient compliance, and streamline healthcare workflows. This review explores the current landscape of PFS in biologic drug delivery, highlighting key innovations in syringe design, material selection, and integration with self-injection devices such as autoinjectors. Particular attention is given to formulation and stability challenges unique to biologics, including protein aggregation, interactions with syringe components, and cold chain requirements. Advances such as silicone-free syringes, dual-chamber systems, and smart connected devices are discussed in the context of improving usability and safety. Regulatory considerations, including human factors, engineering and post-market surveillance, are examined to underscore the importance of risk mitigation in PFS development. Finally, the paper discusses market trends, accessibility challenges, and future directions aimed at optimizing the delivery of biologic drugs through prefilled syringe technologies. As biologics continue to dominate therapeutic pipelines, PFS innovations will play a critical role in supporting safe, effective, and patient-friendly drug administration.

Keywords: Prefilled Syringe; Biologics; Safety; Silicone free; Extractables & Leachables; Auto injector; Human Factors; Container Device Combination, PFS

Introduction

Biologic drugs, comprising proteins, peptides, monoclonal antibodies, nucleic acids, and vaccines, have transformed the landscape of therapeutic interventions for numerous chronic and complex diseases, including cancer, autoimmune disorders, and infectious diseases. Unlike small molecule drugs, biologics are typically large, complex molecules that are sensitive to environmental factors such as temperature, pH, and mechanical stress. Consequently, their administration often requires parenteral routes—mainly subcutaneous or intravenous injections—to preserve their structural integrity and therapeutic efficacy (Makwana et al., 2011; Alcoforado et al., 2019).

Traditionally, biologics were delivered using vials and ampoules, which require multiple preparation steps, including reconstitution, dose measurement, and drawing up the medication into a syringe. This multi-step process increases the risk of dosing errors, microbial contamination, and drug wastage, which is especially critical given the high cost and sensitivity of biologic drugs (Mirasol, 2018). Moreover, the complexity and time-consuming nature of traditional parenteral administration pose barriers for patient self-administration, which is becoming increasingly important with the rise of home-based and outpatient care.

Prefilled syringes (PFS) offer a compelling solution by providing a ready-to-use, pre-measured, sterile drug delivery system that simplifies administration and enhances safety. They reduce preparation errors, lower contamination risks, and improve patient convenience, thereby supporting better adherence to treatment regimens (Forcinio H, 2024). This patient-centric approach is particularly relevant for biologics used in chronic diseases where repeated, long-term administration is common.

However, the transition from traditional vials to PFS for biologics is not without challenges. The physicochemical fragility of biologics demands that the container system preserves drug stability over the product’s shelf life. Factors such as interaction with container materials, silicone oil lubrication, particulate generation, and temperature fluctuations during storage can lead to protein aggregation, loss of potency, or immunogenic responses (Makwana et al., 2011; Mirasol, 2018).

Furthermore, the growing demand for high-concentration biologics introduces additional hurdles such as increased solution viscosity, requiring optimization of syringe design and injection force to maintain patient comfort and dose accuracy. Material science innovations, such as the shift from traditional glass to advanced polymer syringes (cyclic olefin polymers), have begun addressing concerns related to breakage and interaction with drug substances (PharmTech, 2024).

2. Materials and Basic Design of Prefilled Syringes

2.1 Glass Syringes

Glass, particularly Type I borosilicate, has long been the material of choice for syringes due to its excellent chemical inertness, transparency, and barrier properties against moisture and oxygen. However, glass is brittle and prone to breakage, posing safety risks and potentially leading to dose loss. Additionally, the manufacturing process can leave residual tungsten particles used in needle hole drilling, which may catalyse protein aggregation in biologic formulations (Makwana et al., 2011).

2.2 Polymer Syringes (COP/COC)

The introduction of cyclic olefin polymers (COP) and cyclic olefin copolymers (COC) offers several advantages: reduced weight, excellent break resistance, and suitability for cryogenic storage. COP syringes also reduce protein adsorption and aggregation risks compared to glass (Abdulrahman A et al., 2022).

2.3 Lubrication and Surface Treatments

Silicone oil is conventionally used as a lubricant to reduce plunger glide force and enable smooth injection. However, silicone oil microdroplets can interact with proteins, leading to aggregation and subvisible particle formation, which are linked to immunogenicity concerns (Chisholm CF, et al.,2016).

Emerging silicone-free syringes or those with ultra-low silicone coatings (e.g., “Zero Residual™” syringes) use alternative surface treatments to reduce these risks while maintaining acceptable glide forces (Gjolberg, T 2022).

Material / Component	Benefits	Potential Uses / Applications
Borosilicate Glass (Type I) (Witzman A et al.; 2009)	Excellent chemical inertness and transparency- High barrier to moisture and gases- Well-established regulatory acceptance	Standard for injectable biologics requiring high stability- Suitable for long-term storage of sensitive proteins and monoclonal antibodies
Cyclic Olefin Polymer (COP) (Andrea S, et. al., 2010)	High break resistance, lightweight- Excellent clarity and chemical resistance- Suitable for low-temperature storage-	High-concentration biologics requiring break-resistant containers- Cold chain biologics needing flexible packaging- Products prone to silicone-oil related aggregation
Cyclic Olefin Copolymer (COC) (Andrea S, et. al., 2010)	Similar benefits to COP- Improved flexibility and processability	Biologics with moderate stability requirements- Devices needing combination with complex delivery systems (e.g., auto-injectors)
Elastomeric Stoppers and Plungers (Silicone-coated or Silicone-free) (Danielle L 2007)	Provides airtight seal- Silicone coating reduces glide force for smooth injection- Silicone-free variants reduce protein interaction risks	Critical for maintaining container closure integrity- Used with glass or polymer syringes in biologics delivery
Silicone Oil (Lubricant) (Bernstein R 1987)	Reduces plunger glide force- Facilitates ease of injection	Standard lubrication in most PFS- Silicone-free alternatives used where protein aggregation risk is high
Polymer Coatings (Barrier or Siliconization) (Fradkin AH, et. al., 2010)	Improve glide force without silicone oil- Reduce interaction between protein and container surface- Enhance moisture/oxygen barrier properties	Advanced syringes designed to minimize protein aggregation- Syringes for sensitive biologics requiring low particle counts
Polypropylene / Polyethylene (Caps, Needle Shields) (Fradkin AH, et. al., 2010)	Lightweight, cost-effective- Biocompatible and chemically inert	Needle shields and syringe caps- Secondary components aiding safe handling and dosing
Needle (Stainless Steel) (Tyagi AK, et. al., 2009)	High strength and sharpness- Corrosion resistance- Biocompatible	Standard for injection through skin- Various gauge sizes for different viscosities and injection sites
Needle Coatings (Silicone, PTFE) (Bernstein R 1987)	Reduce insertion force- Minimize patient pain- Prevent needle coring	Enhanced patient comfort during injection- Reduce damage to drug during delivery
Rubber Elastomeric Seals (Butyl Rubber) Makwana et al., 2011)	Maintain airtight, sterile environment- Compatible with biologic formulations	Used as seals in syringe plungers and vial stoppers to ensure container closure integrity
Barrier Films (for Packaging) (Makwana et al., 2011)	Protect syringes from moisture, oxygen, and light exposure	Packaging material for polymer syringes or sensitive biologics to enhance shelf life
Smart Sensor Integration (e.g., Bluetooth, RFID) Makwana et al., 2011;	Enables dose tracking, adherence monitoring- Provides injection feedback	Smart prefilled syringe systems for chronic disease management and telemedicine
Finger Flanges / (Tyagi AK, et. al., 2009)	Improve syringe handling and control- Reduce injection errors	Useful for patients with limited dexterity or self-administration

3. Biologic-Specific Formulation and Stability Challenges

Biologic drugs, primarily composed of large, complex protein molecules, present unique formulation and stability challenges that require meticulous consideration during the development of prefilled syringe (PFS) products. Unlike small-molecule drugs, biologics are inherently sensitive to their environment due to their complex tertiary and quaternary structures. These delicate structures are susceptible to physical and chemical degradation that can compromise therapeutic efficacy and patient safety (Wang, 2005; Robinson et al., 2010).

3.1. Protein Instability and Degradation

One of the most significant challenges in biologic formulation is managing protein instability. Physical instability often manifests as protein aggregation, where individual protein molecules clump together, forming soluble or insoluble aggregates. This phenomenon can be triggered by a variety of stresses encountered during manufacturing, storage, and administration, such as mechanical agitation, temperature fluctuations, and interactions with the surfaces of the syringe or silicone oil lubricants used to facilitate plunger movement (Akbarian, M et al., 2022). Aggregation not only reduces the biologic’s potency but also increases the risk of immunogenicity, as aggregates can be recognized by the immune system as foreign, potentially causing adverse immune reactions in patients (Schellekens, 2002). In addition to aggregation, proteins can undergo denaturation, a process where the native folded structure unfolds due to exposure to extremes of pH, shear forces, or interfaces such as air-liquid boundaries, leading to loss of biological activity (Wang, 2005).

3.2 Chemical Instability

Chemical degradation is another critical challenge. Biologics are vulnerable to reactions such as oxidation, deamidation, hydrolysis, and isomerization. Oxidation is particularly problematic, often targeting methionine, tryptophan, or cysteine residues, resulting in altered protein function or increased immunogenicity. The susceptibility of biologics to chemical degradation is influenced heavily by formulation factors, including buffer composition, pH, excipient interactions, and exposure to light or oxygen during storage. The careful selection of formulation excipients, such as antioxidants and chelators, can mitigate these effects but requires extensive analytical validation (Robinson et al., 2010).

3.3 Interaction with Container and Delivery System

The container and delivery system itself can also affect biologic stability. Silicone oil, widely used to lubricate syringe plungers and facilitate smooth administration, can shed droplets into the drug solution. This silicone oil can interact with proteins, promoting aggregation, especially when the syringe is subjected to mechanical stress or temperature changes. To address this, manufacturers are exploring silicone-free or ultra-low silicone coatings as alternatives. Additionally, leachables and extractables from syringe components such as elastomeric stoppers, polymer barrels, and adhesives may migrate into the formulation, posing risks of chemical interaction with the biologic drug (Danielle L 2007). Comprehensive extractables and leachables studies are therefore critical to ensure compatibility and patient safety (Ratanji et al., 2014).

3.4 High Concentration Formulations

High-concentration formulations present yet another set of challenges. To reduce injection volume and improve patient convenience, particularly important in self-administration scenarios, biologics are often formulated at very high concentrations, sometimes exceeding 200 mg/mL (Thiesson I, 2025). However, increased concentration leads to increased viscosity, making injection more difficult and potentially uncomfortable for patients. High viscosity also complicates manufacturing processes such as aseptic filling and device compatibility. Overcoming these obstacles requires innovative formulation approaches, including the use of viscosity-reducing excipients and protein engineering to reduce self-association tendencies (Tadros et al., 2022).

3.5 Freeze-Thaw and Temperature Sensitivity

Temperature sensitivity is a major hurdle for biologics stored in prefilled syringes. Many biologics require stringent cold chain storage conditions (typically 2–8°C), and any deviations - such as freeze-thaw cycles - can induce protein aggregation and loss of activity. Freeze-thaw stress is especially damaging to proteins, and formulations must incorporate cryoprotectants and stabilizers to protect against damage during freezing and thawing. In some cases, lyophilized (freeze-dried) formulations are preferred, though this requires reconstitution prior to injection, which negates some benefits of prefilled syringes (Yu, Y. B. et al., 2021).

3.6 Immunogenicity Risks

Finally, the risk of immunogenicity remains a paramount concern. Protein aggregates, chemical modifications, and impurities can trigger unwanted immune responses ranging from the production of neutralizing antibodies to severe hypersensitivity reactions. Therefore, developers must employ a multi-pronged strategy involving rigorous control of manufacturing processes, thorough characterization of degradation products, and use of formulation components that minimize immunogenicity risk (Schellekens, 2002).

4. Features in PFS Design

4.1 Silicone-Free Syringes and Surface Modifications

Silicone-free syringes use specialized coatings or materials to eliminate or drastically reduce silicone oil use, thereby minimizing protein aggregation and subvisible particles (Werner B 2018). Ultra-low silicone coatings also aim to achieve a balance between glide force and particle generation

4.2 Advanced Glass Coatings:

The application of novel glass coatings, such as platinum siliconization, has been shown to reduce protein aggregation by up to 20%, thereby extending the stability of biologic drugs (Witzman A et al.; 2009).

4.3 Plastic Syringes with Integrated Retractable Needles:

The introduction of plastic syringes featuring integrated retractable needle systems has reduced accidental needlestick injuries by approximately 45%, enhancing safety for healthcare professionals and patients (Market Growth Reports)

4.4 Dual-Chamber Syringes and Reconstitution Systems

Some biologics require reconstitution just before administration. Dual-chamber syringes separate lyophilized drug and diluent, simplifying preparation and reducing contamination risks. Innovations include systems that mix components automatically during injection, streamlining self-administration (Rahul G, 2021).

4.5 Integration with Auto-Injectors and Safety Features

Auto-injectors are increasingly used with PFS for self-administration, enabling consistent, user-friendly injection with hidden needles and controlled injection speeds to improve patient adherence (Mirasol, 2018). Safety features like passive needle guards reduce needlestick injuries.

4.6 Needle Shields and Auto-Disable Mechanisms:

The incorporation of needle shields and auto-disable mechanisms prevents syringe reuse and accidental needle sticks, ensuring safer administration, particularly in outpatient and home-care settings (Rahul G, 2021).

4.7 Automated Visual Inspection Systems:

The implementation of automated visual inspection (AVI) systems, such as those developed by Antares, enables high-throughput detection of particles, air bubbles, cracks, and fill-level discrepancies, ensuring consistent product safety and compliance with regulatory standards Business Wire.

4.8 RFID-Enabled Syringes:

The incorporation of RFID tags allows for real-time tracking and authentication, which is particularly beneficial in vaccine distribution to prevent counterfeiting (Werner B 2018)

4.9 Packaging and Barrier Enhancements

For COP syringes, barrier packaging protects against moisture and oxygen ingress. Additionally, ready-to-use packaging reduces handling errors and contamination risks. Recent advances include light-protective films and nested trays for efficient transport and storage (Ninomiya et al., 2001)

4.10 Ergonomic Designs:

Devices such as AptarGroup's Click2Pen feature ergonomic designs that simplify the injection process, making it more accessible for patients with manual dexterity issues (Rahul G, 2021).

4.11 Pre-assembled Components:

The inclusion of pre-assembled needles and retractable systems reduces assembly time and complexity, enhancing overall user experience (Market Growth Reports).

5. Regulatory, Quality Control, and Safety Considerations

5.1 Regulatory Landscape

Prefilled syringes (PFS) are classified as combination products since they integrate both a drug and a delivery device, making their regulatory approval complex. Regulatory agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and International Council for Harmonisation (ICH) provide comprehensive guidelines that address both pharmaceutical and device aspects (Danielle L, 2007). Manufacturers must comply with stringent regulations encompassing material biocompatibility, container closure integrity, and drug-device compatibility to ensure product safety and efficacy. Recent regulatory updates emphasize risk management strategies to address emerging challenges related to novel materials and device functionalities (Andrea S, 2010).

5.2 Quality Control Measures

Quality control in PFS production involves rigorous testing at multiple stages to maintain sterility, dosing accuracy, and mechanical integrity. Critical parameters include syringe dimensional conformity, needle sharpness, plunger movement force, and siliconization levels that affect drug stability and injection comfort. Process validation for aseptic fill-finish operations ensures contamination-free manufacturing, with environmental monitoring and microbial testing being essential components (Li et al., 2021).

5.3 Safety Considerations

Safety is paramount in PFS design and use. Syringes must incorporate features to minimize needle-stick injuries, such as retractable needles or needle shields, complying with OSHA and ISO 23908 standards (Makwana S.,2011). Moreover, material selection plays a significant role in reducing immunogenicity and hypersensitivity reactions, particularly for biologic drugs susceptible to protein aggregation triggered by syringe surface interactions. Stability studies under accelerated and real-time conditions confirm that PFS maintain drug potency and sterility throughout shelf life, thus preventing adverse events related to compromised product quality (Li et al., 2021).

5.4 Post-Market Surveillance and Pharmacovigilance

After regulatory approval, ongoing monitoring of PFS safety and performance is mandatory. Post-market surveillance programs collect real-world data on device malfunctions, adverse drug reactions, and patient usability issues. Feedback loops enable manufacturers to implement design improvements and address recalls promptly, ensuring continuous risk mitigation (Li et al., 2021). Integration of digital health tools in smart PFS devices also enhances pharmacovigilance by providing timely data on drug administration patterns and potential safety signals (Deiringer N et al., 2021).

6. Market trends in prefilled syringes

6.1 Manufacturing and Fill-Finish Innovations

The manufacturing of prefilled syringes has evolved significantly to meet the rising demand for biologics and patient-centric drug delivery systems. Modern fill-finish processes emphasize automation, sterility, and efficiency. Robotic systems are increasingly integrated into aseptic filling lines, improving precision and reducing contamination risks. (Fortune business insights 2025).

Additionally, tub-based standardized filling systems have become popular for their efficiency in washing, siliconizing, sterilizing, and filling syringes. These systems reduce variability and increase throughput, meeting industry demands for scalability and quality (Thiesson I.et al., 2025)

Cold chain management and lyophilization are other critical areas of innovation. Lyophilized biologics packaged in prefilled syringes show enhanced stability and longer shelf lives, addressing the sensitivity of biologics to temperature and storage conditions (Li et al., 2021).

6.2 Market Trends

The global prefilled syringes market is experiencing robust growth, projected to exceed USD 70 billion by 2033, driven largely by the increasing prevalence of chronic diseases, aging populations, and the expanding biologics sector. Prefilled syringes are favoured for biologic drug delivery due to their convenience, dose accuracy, and improved patient adherence (Root analysis, 2025).

Technological innovations such as smart packaging (e.g., Gerresheimer's SmartPack) and user-friendly delivery devices (e.g., AptarGroup’s Click2Pen) are enhancing the safety and usability of prefilled syringes. These innovations are complemented by the development of more durable and break-resistant syringe materials, such as SCHOTT’s OPTIMA glass (SCHOTT Pharma, 2024)

6.3 Regional Insights

North America currently dominates the fill-finish manufacturing market, accounting for over one-third of global production, driven by technological advances and strong biologics demand. Meanwhile, the Asia-Pacific region is the fastest-growing market, benefiting from increased healthcare investments and rising access to biologic therapies (Root analysis, 2025).

7. Recent Developments in Prefilled Syringes Market (Root analysis, 2025)

Several recent developments have taken place in the field of prefilled syringes, some of which are outlined below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we have outlined in our analysis.

In June 2024, Sharps Services announced expansion at its Pennsylvania site for secondary packaging of sterile injectables, including prefilled syringe assembly and labeling.
In June 2024, Schott Pharma opened a new production facility at Lukácsháza, Hungary to expand its glass prefilled syringe manufacturing capacity. The facility has been built with an investment of EUR 76 million.
In October 2023, West Pharmaceutical Services participated in 2023 PDA Universe of Pre-Filled Syringes and Injection Devices Conference, held in Gothenburg, Sweden to showcase its expertise in large volume delivery systems, self-injection devices and pre-fillable syringe components.
In August 2023, Becton Dickinson expanded its collaboration with Bill & Melinda Gates Foundation, Children’s Investment Fund Foundation (CIFF) and Pfizer to deliver over 320 million doses of Pfizer’s injectable contraceptive, Sayana® Press, which is administered by BD’s Uniject™ Auto-Disable Prefillable Injection System, through 2030.
In July 2023, Fresenius Kabi launched Simplist® Ready-to-Administer Prefilled Syringes comprising of Fentanyl Citrate Injection.
In May 2023, Becton Dickinson expanded the customer availability of its prefilled flush syringe with an integrated disinfection unit.
In May 2023, SCHOTT AG launched pre-fillable syringes made from advanced, pharmaceutical-grade polymers to deliver deep-cold drugs
In May 2023, Medefil launched Atropine Sulfate Injection, USP, 1 mg/10 mL to treat bradyasystolic cardiac arrest

Therapeutic Syringes	Blood Disorders, Infectious Diseases, Autoimmune Disorders, Oncological Disorders, Cardiovascular Disorders, Respiratory Disorders, Neurological Disorders, Metabolic Disorders, Ophthalmic & Orthopedic Disorder
Type of Molecule (Therapeutic Syringes)	Proteins, Antibodies, Peptides, Small Molecules, Vaccines Cell Therapies
Type of Barrel Material	Glass Syringe, Plastic Syringe
Number of Barrel Chamber	Single Chamber Syringe, Dual Chamber Syringe
Type of Needle System	Staked Needle Syringe, Luer Syringe
Usability of Syringe	Disposable Syringe, Reusable Syringe
Type of Syringe	Conventional Syringe, Safety Syringe
Type of Packaging	Bulk Syringe, Nested Syringe
Key Players	Becton Dickinson and Company, Credence MedSystems Gerresheimer, J.O.Pharma, Medefil, MedXL, Mitsubishi Gas Chemical, Nipro Pharma Packaging, Novartis, Pfizer, SCHOTT, Shandong Pharmaceutical Glass, Shandong Weigao, Shin Yan Sheno Precision Industrial, Stevanato, Taisei Kako, Vetter Pharma, West Pharmaceutical
Key Geographical Regions	North America (US and Canada), Europe (Germany, France, Italy, Spain, UK, Rest of Europe), Asia-Pacific (Japan, India, China, Australia, South Korea, Rest of Asia Pacific), Middle East and North Africa, Latin America

7.2 Marketed product of Prefilled syringes (Root analysis, 2025, Technavio 2024)

Brand Name	Therapeutic Use	Manufacturer
Humira Pen	Autoimmune diseases (rheumatoid arthritis, Crohn's disease)	AbbVie
Enbrel SureClick	Autoimmune diseases (rheumatoid arthritis, psoriasis)	Amgen
Copaxone	Multiple sclerosis	Teva Pharmaceuticals
Lantus SoloStar	Diabetes	Sanofi
NovoLog FlexPen	Diabetes	Novo Nordisk
EpiPen	Anaphylaxis	Mylan (now Viatris)
Prolia	Osteoporosis	Amgen
Repatha Pushtronex	High cholesterol	Amgen
Xolair	Asthma, chronic urticaria	Genentech (Roche Group)
Ibrance	Breast cancer	Pfizer

8. Benefits of Prefilled Syringes Over Other Injectable Dosage Forms

Prefilled syringes (PFS) offer multiple advantages compared to conventional vial-and-syringe systems and other injectable dosage forms, contributing to their growing preference in pharmaceutical and healthcare settings:

8.1 Improved Dosing Accuracy and Precision

PFS come preloaded with a precise, pre-measured dose, significantly reducing dosing errors that can occur with manual drawing from vials. This ensures consistent and accurate administration of the intended drug quantity, critical for biologics and potent medications (Michael NE, 2008).

8.2 Enhanced Safety

The risk of needle-stick injuries is lower with PFS since they eliminate the need for drawing medication from vials and often incorporate safety-engineered needle shields or retractable needless (Michael NE, 2008)

8.3 Reduced Risk of Contamination

Because the drug is sealed in a sterile syringe, PFS minimize the potential for microbial contamination associated with vial access, thus maintaining sterility throughout the product’s shelf life and reducing infection risks during administration (Li et al., 2021).

8.4 Convenience and Time Efficiency

PFS streamline the preparation and administration process by eliminating several steps such as vial opening, dose measurement, and syringe filling. This saves valuable time for healthcare providers and reduces complexity, especially in emergency or high-volume settings (Andrea S, 2010).

8.5 Improved Patient Compliance and Experience

Prefilled syringes are designed to be user-friendly and are often used with autoinjectors or pen devices, facilitating self-administration by patients. (Denise B 2007).

8.6 Facilitation of Biologic Drug Delivery

Biologic drugs are often sensitive to handling and environmental factors. PFS provide a controlled, stable environment, reducing degradation risks associated with manual handling and enhancing product stability (Li et al., 2021).

9. Future Directions and Scope of Advancement of Prefilled Syringes (PFS)

The future of prefilled syringes (PFS) in pharmaceutical and healthcare sciences is poised for remarkable advancements, driven by evolving patient needs, innovative technologies, and expanding therapeutic landscapes. Several key areas indicate the direction of ongoing research and development:

9.1 Smart and Connected Prefilled Syringes

The integration of digital technologies into PFS is an emerging trend aimed at improving patient adherence, dosage accuracy, and monitoring. Smart PFS devices embedded with sensors and connectivity features can record injection times, doses, and patient compliance data. This data can be transmitted to healthcare providers or apps, facilitating personalized treatment and early intervention for non-compliance or adverse events (Andrea S, 2010).

9.2 Advanced Materials and Biocompatibility

The development of novel materials such as cyclic olefin polymers (COP) and advanced silicone-free coatings is enhancing the safety and stability of PFS, particularly for sensitive biologics prone to aggregation or interaction with syringe components. These materials reduce risks of leachables, extractables, and immunogenicity, improving patient safety and product shelf-life (Li et al., 2021).

9.3 Innovative Delivery Systems

Future PFS designs are expected to incorporate enhanced ergonomics and patient-friendly features, such as easier gripping surfaces, improved needle safety mechanisms, and low-force injection systems. These improvements will support self-administration, especially in elderly or physically challenged patients, thus broadening the scope of outpatient and home-based therapies (Glenn AT 2006).

9.4 Personalized Medicine and Dose Flexibility

The advent of personalized medicine demands customizable dosing options. Modular PFS systems that allow dose adjustments without compromising sterility or stability are under investigation. These systems would accommodate the administration of variable dosages based on individual patient pharmacokinetics, potentially improving therapeutic outcomes (Root analysis, 2025).

9.5 Sustainability and Eco-Friendly Design

Environmental concerns are pushing the industry toward sustainable PFS manufacturing, including recyclable materials, reduced packaging waste, and greener production processes. Efforts to develop biodegradable syringes or reusable components will align the pharmaceutical industry with global sustainability goals (EMEA, 2022).

9.6 Regulatory and Standardization Evolution

With increasing innovations, regulatory bodies are updating guidelines to address new risks, such as cyber security in smart devices and biocompatibility of new materials. Harmonization of global standards will be critical to expedite approvals and ensure quality across markets (FDA, 2023; ISO, 2015).

Conclusion

Prefilled syringes have emerged as a pivotal innovation in the delivery of biologic drugs, offering significant advantages in terms of convenience, dosing accuracy, sterility, and patient adherence. The ongoing advancements in materials, design features, and manufacturing technologies have enhanced the safety profile and usability of PFS, making them indispensable in modern pharmaceutical care, particularly for biologics and chronic therapies.

Recent innovations such as smart connectivity, novel bio-compatible materials, and ergonomic delivery systems are transforming PFS into sophisticated drug delivery platforms tailored to meet diverse patient needs. Additionally, regulatory and quality control frameworks continue to evolve to address emerging challenges associated with new materials and digital integration, ensuring patient safety and product reliability.

The future of prefilled syringes lies in the convergence of personalized medicine, digital health, and sustainable manufacturing practices. By embracing these directions, the pharmaceutical industry can expand the therapeutic potential of biologics while improving patient outcomes and reducing healthcare burdens. Ultimately, the continuous development and adoption of advanced PFS technologies will play a crucial role in shaping the future of parenteral drug delivery.

References

1. Agha, A., Waheed, W., Alamoodi, N., Mathew, B., Alnaimat, F., Abu-Nada, E., Abderrahmane, A., & Alazzam, A. (2022). A review of cyclic olefin copolymer applications in microfluidics and microdevices. Macromolecular Materials and Engineering, 307(8), 2200053

2. Akbarian, M., & Chen, S. H. (2022). Instability challenges and stabilization strategies of pharmaceutical proteins. Pharmaceutics, 14(11), 2533

3. Alcoforado, L., Ari, A., Barcelar, J. D. M., Brandão, S. C. S., Fink, J. B., & de Andrade, A. D. (2019). Impact of gas flow and humidity on trans-nasal aerosol deposition via nasal cannula in adults: A randomized cross-over study. Pharmaceutics, 11(7), 320.

4. Andrea, S., & Nuova, O. (2010). Fine tuning of process parameters for improving biocompatibility of prefillable syringes. East Sussex, United Kingdom: Frederick Furness Publishing.

5. Beele, D. (2007). Increasing popularity of prefilled syringes. Packazine, 1, 4–5.

6. Bernstein, R. (1987). Clouding and deactivation of clear (regular) human insulin: Association with silicone oil from disposable syringes? Diabetes Care, 10(6), 786–787. https://doi.org/10.2337/diacare.10.6.786

7. Chisholm, C. F., Baker, A. E., Soucie, K. R., Torres, R. M., Carpenter, J. F., & Randolph, T. W. (2016). Silicone oil microdroplets can induce antibody responses against recombinant murine growth hormone in mice. Journal of Pharmaceutical Sciences, 105(5), 1623–1632.

8. Danielle, L. (2007). Advanced innovations on a new generation of plastic prefilled syringes. East Sussex, United Kingdom: Frederick Furness Publishing. (pp. 8–13).

9. European Medicines Evaluation Agency (EMEA). (2002). Note for guidance on quality of water for pharmaceutical use.

10. European Pharmacopoeia Commission. (2005). 3.2.9 Rubber closures for containers for aqueous parenteral preparations, for powders and for freeze-dried powders. European Pharmacopoeia, 9, 5545–5546.

11. Fradkin, A. H., Boand, C. S., Eisenberg, S. P., Rosendahl, M. S., & Randolph, T. W. (2010). Recombinant murine growth hormone from E. coli inclusion bodies: Expression, high-pressure solubilization and refolding, and characterization of activity and structure. Biotechnology Progress, 26(3), 743–749.

12. Gjolberg, T. T., Lode, H. E., Melo, G. B., Mester, S., Probst, C., Sivertsen, M. S., Jorstad, O. K., Andersen, J. T., & Moe, M. C. (2022). A silicone oil-free syringe tailored for intravitreal injection of biologics. Frontiers in Ophthalmology, 2, 8

13. Glenn, A. T. (2006). Prefillable syringes: Trends and growth strategies. West Sussex, United Kingdom: ON Drug Delivery Ltd.

14. Forcinio, H. (2024). Innovations in prefilled biologics. Pharmaceutical Technology, 48(4), 24–27.

15. International Organization for Standardization. (2015). ISO 11040-1: Prefilled syringes — Part 1: Terminology and general requirements. Geneva, Switzerland: ISO.

16. Li, M., & Chen, J. (2022). Extractables and leachables in prefilled syringes: Regulatory and quality perspectives. Pharmaceutical Technology Europe, 34(7), 25–32.

17. Mirasol, L. (2018). Innovations in prefilled syringes for biologic drugs. BioPharm International, 31(11).

18. Makwana, S., Basu, B., Makasana, Y., & Dharamsi, A. (2011). Prefilled syringes: An innovation in parenteral packaging. International Journal of Pharmaceutical Investigation, 1(4), 200–206.

19. Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010). edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics, 26(1), 139–140.

20. Michael, N. E. (2008). Offering a new choice in glass prefillable syringes. In The American Pharmaceutical Review (pp. 8–12). West Sussex, United Kingdom: ON Drug Delivery Ltd.

21. Ninomiya, N., Koido, Y., & Yamamoto, Y. (2001). Aseptic efficacy of prefilled syringes in a polluted environment. Prehospital and Disaster Medicine, 16(1), 14–17. https://doi.org/10.1017/S1049023X00001368 (if DOI available; add if known)

22. Deiringer, N., Haase, C., Wieland, K., Zahler, S., Haisch, C., & Friess, W. (2021). Finding the needle in the haystack: High-resolution techniques for characterization of mixed protein particles containing shed silicone rubber particles generated during pumping. Pharmaceutics, Drug Delivery and Pharmaceutical Technology, 110(5), 2093–2104

23. Roots Analysis. (2025, September). Prefilled Syringes Market (7th Edition). https://www.rootsanalysis.com/reports/prefilled-syringes-market/284.html Roots Analysis+2Market Publishers+2

24. Fortune Business Insights. (2025, September 22). Prefilled Syringes Market Size, Share & Industry Analysis. https://www.fortunebusinessinsights.com/industry-reports/prefilled-syringes-market-101946 Grand View Research+1

25. MarketGrowthReports. (n.d.). Prefilled Syringes Market Size, Share, Growth, and Industry Analysis, By Type (Glass Prefilled Syringes, Plastic Prefilled Syringes), By Application (Vaccine, Antithrombotic Drugs, Bioengineered Drugs), Regional Insights and Forecast to 2033. www.marketgrowthreports.com/market-reports/prefilled-syringes-market-112427

26. Soikes, R. (2011, February 11). Prefilled Syringes: Challenges, Innovations And Market. PharmTech. https://www.pharmtech.com/view/prefilled-syringes-challenges-innovations-and-market

27. Ingle, R. G., & Fang, W.-J. (2021). Prefilled dual chamber devices (DCDs) – Promising high-quality and convenient drug delivery system. International Journal of Pharmaceutics, 597, 120314.

28. Ratanji, K. D., Derrick, J. P., Dearman, R. J., & Kimber, I. (2014). Immunogenicity of therapeutic proteins: Influence of aggregation. Journal of Immunotoxicology, 11(2), 99–109.

29. Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010). edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics, 26(1), 139–140.

30. Schellekens, H. (2002). Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clinical Therapeutics, 24(11), 1720–1739.

31. SCHOTT Pharma. (2024, January 24). Protecting drugs at deep-cold temperatures: SCHOTT Pharma launches new vials for mRNA and gene therapy

32. Tadros, E., Durante, K. A., McKay, T., Barbini, M., & Hollie, B. (2022). Mental health, perceived consensus of coparenting, and physical health among incarcerated fathers and their nonincarcerated, romantic partners. Families, Systems, & Health, 40(2), 210–224.

33. Technavio. (2024, June). Health care supplies: Prefilled syringes market analysis.

34. Thiesson, I., & Sander, J. (2025, January). Tub & nest – Precision and efficiency in drug delivery. ONdrugDelivery, 168, 112–114.

35. Tyagi, A. K., Randolph, T. W., Dong, A., Maloney, K. M., C. H., & Carpenter, J. F. (2009). IgG particle formation during filling pump operation: A case study of heterogeneous nucleation on stainless steel nanoparticles. Journal of Pharmaceutical Sciences, 98(1), 94–104.

36. U.S. Food and Drug Administration. (2023). 21 CFR Part 820 – Quality system regulation. FDA.

37. Van der Linden, H., van der Plas, D., van Dongen, J. W., & van Dongen, A. (2021). Advances in polymer-based prefilled syringes for biologics: Materials, design, and applications. Journal of Pharmaceutical Sciences, 110(3), 1123–1138.

38. Ingle, R. G., & Fang, W.-J. (2021). Prefilled dual chamber devices (DCDs) – Promising high-quality and convenient drug delivery system. International Journal of Pharmaceutics, 597, 120314.

39. Wang, F., & Hannafin, M. J. (2005). Design-based research and technology-enhanced learning environments. Educational Technology Research & Development, 53(4), 5–23.

40. Werner, B., Schöneich, C., & Winter, G. (2018). Silicone oil-free polymer syringes for the storage of therapeutic proteins. Journal of Pharmaceutical Sciences, 108(1), 10–18.

41. Witzman, A., & Trinks, U. (2009). Encoding and reading of codes on glass containers for pharmaceutical and diagnostic products. Pharmazeutische Industrie, 71, 1945–1948.

42. Yu, Y. B., Briggs, K. T., Taraban, M. B., Brinson, R. G., & Marino, J. P. (2021). Grand challenges in pharmaceutical research series: Ridding the cold chain for biologics. Pharmaceutical Research, 38(1), 3–7.